Roivant Sciences director sells 17,750 shares

The director's two sales were made under a Rule 10b5-1 trading plan adopted March 30, 2026.

Rhea-AI Filing Summary

Roivant Sciences Ltd. director Melissa B. Epperly exercised options for 17,750 common shares on October 1, 2026, at $4.46 per share. She sold 16,850 shares at a weighted-average $36.08 per share (range $35.46–$36.45) and 900 shares at a weighted-average $36.57 per share (range $36.48–$36.72), under a Rule 10b5-1 trading plan adopted March 30, 2026. Her reported stock-option balance following the transaction was 151,416 options.

Insider Trade Summary 10b5-1

Exercise and sale activity reported; no spread calculated

Exercise and Sale 4 txns

Insider Epperly Melissa B,

Role Director

Sold 17,750 shs ($641K)

Approx. gross sale proceeds $641K

Approx. exercise cost $79K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy) F3	17,750	$0.00	$0.00
Exercise	Common Shares	17,750	$4.46	$79K
Sale	Common Shares F1	16,850	$36.08	$608K
Sale	Common Shares F2	900	$36.57	$33K

Holdings After Transaction: Stock Option (Right to Buy) — 151,416 contracts (Direct); Common Shares — 14,954 shares (Direct)

Footnotes (3)

1. F1. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.46 to $36.45, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 30, 2026.
2. F2. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.48 to $36.72, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 30, 2026.
3. F3. Reflects an award of stock options to purchase Common Shares that is fully vested.

Key Figures

Options exercised: 17,750 shares Exercise price: $4.46 per share First sale block: 16,850 shares +4 more

7 metrics

Options exercised 17,750 shares October 1, 2026

Exercise price $4.46 per share Options exercised on October 1, 2026

First sale block 16,850 shares October 1, 2026

First block weighted-average sale price $36.08 per share October 1, 2026

Second sale block 900 shares October 1, 2026

Second block weighted-average sale price $36.57 per share October 1, 2026

Stock-option balance following transaction 151,416 options Reported after the October 1, 2026 transaction

Key Terms

Rule 10b5-1 trading plan, weighted average price, fully vested

3 terms

Rule 10b5-1 trading plan regulatory

"pursuant to a Rule 10b5-1 trading plan adopted on March 30, 2026"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

fully vested financial

"stock options to purchase Common Shares that is fully vested"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ROIV shares did director Melissa B. Epperly sell?

Melissa B. Epperly reported sales of 16,850 shares at a weighted-average $36.08 per share and 900 shares at a weighted-average $36.57 per share on October 1, 2026. The sales were made under a Rule 10b5-1 trading plan adopted March 30, 2026.

What options did the ROIV director exercise?

Melissa B. Epperly exercised options for 17,750 common shares at $4.46 per share on October 1, 2026. The reported stock-option balance following the transaction was 151,416 options.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/05/2026 - 06:06 PM Accepted by SEC EDGAR 10/05/2026 - 06:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Epperly Melissa B,

(Last) (First) (Middle)

C/O ROIVANT SCIENCES LTD.

7TH FLOOR, 50 BROADWAY

(Street)

LONDON SW1H 0DB

(City) (State) (Zip)

UNITED KINGDOM

(Country)

2. Issuer Name and Ticker or Trading Symbol
Roivant Sciences Ltd. [ ROIV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	10/01/2026		M		17,750	A	$4.46	32,704	D
Common Shares	10/01/2026		S		16,850	D	$36.08(1)	15,854	D
Common Shares	10/01/2026		S		900	D	$36.57(2)	14,954	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$4.46	10/01/2026		M			17,750	(3)	07/19/2032	Common Stock	17,750	$0	151,416	D

Explanation of Responses:

1. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.46 to $36.45, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 30, 2026.

2. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.48 to $36.72, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 30, 2026.

3. Reflects an award of stock options to purchase Common Shares that is fully vested.

Remarks:

	By: /s/ Sam Kaplan, as Attorney-in-Fact for Melissa Epperly	10/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)